Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medpace Holdings (MEDP), Biohaven Ltd. (BHVN) and Intra-Cellular Therapies (ITCI)
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Biohaven Pick of the Week at Smart Insider Following Stock Purchases by CEO, Directors
BofA Securities Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $65
"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.
Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.